A Phase I, Safety and Immunogenicity Trial of the Heterologous Prime-boost Regimen Combining the Monovalent Zaire Ebola Viral Vector Candidates ChAd3-EBO-Z and Ad26.ZEBOV in Healthy UK Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; GSK 3390107A (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 19 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 19 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 25 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2017.